☆ 4.3 Letter

Longer-term response to SARS-CoV-2 vaccine in MPN patients: Role of ruxolitinib and disease severity

LEUKEMIA RESEARCH (2022)

Get Full Text
Add to Collection

Journal

LEUKEMIA RESEARCH
Volume 116, Issue -, Pages -

Publisher

PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.leukres.2022.106819

Keywords

COVID-19; Vaccine; BNT162b2; MPN; Ruxolitinib; Antibody

Categories

Oncology Hematology

Funding

  1. BolognAIL

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available
Webinars Posters Questions Hubs Funding Journals Papers Connect Collections Reviewers About Us FAQs Mobile App Privacy Policy Terms of Use
© Peeref 2019-2024. All rights reserved.